Cytel: Laiya Consulting acquisition
Adaptive clinical trial specialist Cytel has acquired Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. The purchase reportedly expands Cytel’s roster Bayesian experts with the addition of biostatisticians, including University of Chicago professor of biostatistics Yuan Ji.
“As we look to make the benefits of sophisticated Bayesian methods ever more accessible to drug developers, we’re taking strategic leaps to both bolster our core offerings and streamline their delivery to the market,” said Yannis Jemiai, chief scientific officer at Cytel. “Partnering with Laiya allows us to smoothly feed into our broad Bayesian software capabilities with ever greater levels of statistical innovation and expertise.”
